Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial.

David Venet Mattia ReditiMarion MaetensDebora Fumagalli David N BrownSamira MajjajRoberto SalgadoLajos Pusztai Nadia Harbeck Sarra El-AbedYingbo WangCristina Saura Henry L GómezVladimir Fedorovich SemiglazovEvandro de Azambuja Jens Huober Paolo G NuciforoSerena Di CosimoMartine PiccartSherene LoiFrançoise RothéChristos Sotiriou

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Our analysis identified ERBB2 copy number as well as 6q23-24 CNAs as predictors of response to anti-HER2-based treatment. ERBB2 expression outperformed ERBB2 amplification. The complexity of the 6q23-24 region warrants further investigation.

Keyphrases

copy number
mitochondrial dna
clinical trial
phase iii
genome wide
open label
dna methylation
poor prognosis
double blind
stem cells
randomized controlled trial
rectal cancer
bone marrow
combination therapy
smoking cessation